Home > Oncology > ASCO GI 2022 > ASCO GI 2022 Highlights Podcast

ASCO GI 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASCO GI 2022
orig text:

In this episode (20:49 min), Medicom’s correspondent covers 6 presentations from the ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2022) which was held as a hybrid event both virtually and in-person in San Francisco, CA, USA, 20-22 January 2022.
  1. DCF outperforms standard-of-care for locally advanced oesophageal cancer Docetaxel plus neoadjuvant cisplatin and 5-fluorouracil (DCF) chemotherapy was superior to CF chemotherapy alone in patients with locally advanced oesophageal cancer, the primary analysis of the phase 3 JCOG1109 NExT trial showed. Moreover, the toxicity profile of the DCF combination regimen was manageable. Therefore, neoadjuvant DCF represents a new standard therapy for this patient population
  2. DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer The final results of the phase 2 DESTINY-Gastric01 trial showed that trastuzumab deruxtecan (T-DXd) was superior to a standard PC chemotherapy regimen in patients with HER2-positive advanced gastric or gastroesophageal cancer. Also, the updated safety data were consistent with the primary analysis of this study
  3. HIMALAYA: Durvalumab with or without tremelimumab new first-line options for unresectable hepatocellular carcinoma Tremelimumab plus durvalumab improved the overall survival of patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib. Also, durvalumab monotherapy was non-inferior to sorafenib. Durvalumab monotherapy and tremelimumab plus durvalumab had manageable safety profiles and may represent new first-line treatment options for this population.
  4. KEYNOTE-590: New standard-of-care for oesophageal cancer Pembrolizumab plus chemotherapy showed clinically meaningful benefits compared with chemotherapy alone as first-line therapy in patients with locally advanced and metastatic oesophageal cancer. Furthermore, the longer-term follow-up data of the phase 3 KEYNOTE-590 study displayed comparable safety profiles of both treatment options. These results confirm that the pembrolizumab regimen offers a new standard of care for this population.
  5. Nivolumab plus standard-of-care does not meet primary endpoint for colorectal cancer In the phase 2/3 CheckMate 9X8 trial, nivolumab plus standard-of-care did not significantly improve progression-free survival compared with standard-of-care alone in the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, the results numerically favoured patients receiving additional nivolumab. Moreover, patients with CMS1 and CMS3 molecular subtypes, or CD8 levels ≥2% displayed benefits from nivolumab, exploratory analyses revealed [1].
  6. Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma Etoposide and irinotecan showed equal efficacy in a head-to-head study among patients with advanced neuroendocrine carcinoma (NEC) of the digestive system [1]. Therefore, these agents both remain first-line therapeutic options for this population.
Enjoy listening! Copyright ©2022 Medicom Medical Publishers


parsed elements:




Source with stripped tags:

In this episode (20:49 min), Medicom’s correspondent covers 6 presentations from the ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2022) which was held as a hybrid event both virtually and in-person in San Francisco, CA, USA, 20-22 January 2022.
  1. DCF outperforms standard-of-care for locally advanced oesophageal cancer Docetaxel plus neoadjuvant cisplatin and 5-fluorouracil (DCF) chemotherapy was superior to CF chemotherapy alone in patients with locally advanced oesophageal cancer, the primary analysis of the phase 3 JCOG1109 NExT trial showed. Moreover, the toxicity profile of the DCF combination regimen was manageable. Therefore, neoadjuvant DCF represents a new standard therapy for this patient population
  2. DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer The final results of the phase 2 DESTINY-Gastric01 trial showed that trastuzumab deruxtecan (T-DXd) was superior to a standard PC chemotherapy regimen in patients with HER2-positive advanced gastric or gastroesophageal cancer. Also, the updated safety data were consistent with the primary analysis of this study
  3. HIMALAYA: Durvalumab with or without tremelimumab new first-line options for unresectable hepatocellular carcinoma Tremelimumab plus durvalumab improved the overall survival of patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib. Also, durvalumab monotherapy was non-inferior to sorafenib. Durvalumab monotherapy and tremelimumab plus durvalumab had manageable safety profiles and may represent new first-line treatment options for this population.
  4. KEYNOTE-590: New standard-of-care for oesophageal cancer Pembrolizumab plus chemotherapy showed clinically meaningful benefits compared with chemotherapy alone as first-line therapy in patients with locally advanced and metastatic oesophageal cancer. Furthermore, the longer-term follow-up data of the phase 3 KEYNOTE-590 study displayed comparable safety profiles of both treatment options. These results confirm that the pembrolizumab regimen offers a new standard of care for this population.
  5. Nivolumab plus standard-of-care does not meet primary endpoint for colorectal cancer In the phase 2/3 CheckMate 9X8 trial, nivolumab plus standard-of-care did not significantly improve progression-free survival compared with standard-of-care alone in the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, the results numerically favoured patients receiving additional nivolumab. Moreover, patients with CMS1 and CMS3 molecular subtypes, or CD8 levels ≥2% displayed benefits from nivolumab, exploratory analyses revealed [1].
  6. Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma Etoposide and irinotecan showed equal efficacy in a head-to-head study among patients with advanced neuroendocrine carcinoma (NEC) of the digestive system [1]. Therefore, these agents both remain first-line therapeutic options for this population.
Enjoy listening! Copyright ©2022 Medicom Medical Publishers

Posted on